Correlated Drug Terms (2)

---

	Name (Synonyms)	Correlation
drug784	Doctor Spot Wiki	1.00
drug1822	Placebo Wiki	0.06

Correlated MeSH Terms (4)

---

	Name (Synonyms)	Correlation
D021821	Communicable Diseases, Emerging NIH	1.00
D004630	Emergencies NIH	0.19
D003141	Communicable Diseases NIH	0.09
D007239	Infection NIH	0.06

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: SARS-CoV-2 positive subjects are defined as subjects with positive tests for SARS-CoV-2 RT-PCR or for SARS-CoV-2 lgG antibodies after developing COVID-19 disease at any stage within the follow-up period (including those subjects with or without symptomatic COVID-19 evaluated before the final visit) or those individuals who test positive for SARS-CoV-2 RT-PCR or for SARS-CoV-2 lgG antibodies at the final visit (day 60).

Measure: Percentage of SARS-CoV-2 positive subjects

Time: 60 days

---

Measure: Highest mean WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group.

Time: 60 days

---

Secondary Outcomes

Measure: Highest mean WHO score up to day 60 for the active treatment group as compared to placebo among subjects with a positive test received at any moment during the study after the first visit

Time: 60 days

---

Description: Mean change from baseline will be computed

Measure: Total cholesterol, LDL, HDL, triglycerides (mg/dL) at baseline and at day 60

Time: baseline, 60 days

---

Description: Mean change from baseline will be computed

Measure: Ultrasensitive C-reactive Protein (mg/dL) at baseline and at day 60

Time: baseline, 60 days

---

Measure: Difference in hospital length of stay between groups

Time: 60 days

---

Measure: Difference in duration of mechanical ventilation in both groups

Time: 60 days

---

Measure: Rate of hospital admissions due to SARS (Severe Acute Respiratory Syndrome) in patients who were negative for SARS CoV-2 upon admission

Time: 60 days

---

Measure: Mean highest WHO descriptive score in active treatment versus placebo groups up to day 60 among hospitalized patients (WHO grades 3 or more) without serum evidence / PCR detecting SARS-CoV-2 infection

Time: 60 days

---

Measure: Rate of total events, non-fatal myocardial infarction or non-fatal stroke or death (initial and subsequent), up to day 60

Time: 60 days

---